Skip to main content
PLOS One logoLink to PLOS One
. 2021 Feb 8;16(2):e0245163. doi: 10.1371/journal.pone.0245163

The use of complementary and alternative medicine among hypertensive and type 2 diabetic patients in Western Jamaica: A mixed methods study

Omolade Adeniyi 1,, LaTimberly Washington 1,, Christina J Glenn 2, Sarah G Franklin 1, Anniecia Scott 3, Maung Aung 3,, Soumya J Niranjan 4,, Pauline E Jolly 1,‡,*
Editor: Jenny Wilkinson5
PMCID: PMC7870151  PMID: 33556053

Abstract

Background

The simultaneous or intermittent use of alternative treatments and prescription medications for hypertension and type 2 diabetes mellitus can have adverse health effects.

Objectives

To identify beliefs and practices associated with the use of alternative treatments for hypertension and type 2 diabetes mellitus among patients.

Methods

A mixed-methods study including an investigator-administered survey and focus group discussion sessions using convenience sampling was conducted among patients aged ≥18 years during May to August 2018. Descriptive statistics were used to describe and compare demographic characteristics among groups of survey participants using JMP Pro 14.0. Thematic analysis was conducted to analyze the qualitative data using NVivo.

Results

Most study participants (87–90%) were on prescription medication for their condition. Of survey participants, 69% reported taking their medication as prescribed and 70% felt that prescription medicine was controlling their condition. Almost all participants (98%) reported using alternative treatments, mainly herbal medications, and 73–80% felt that herbal medicines controlled their conditions. One-third believed that herbal medicines are the most effective form of treatment and should always be used instead of prescription medication. However, most participants (85%) did not believe that prescription and herbal treatments should be used simultaneously. Most (76–90%) did not discuss herbal treatments with their healthcare providers. Four themes emerged from the focus group sessions: 1) Simultaneous use of herbal and prescription medicine was perceived to be harmful, 2) Patients did not divulge their use of herbal medicine to healthcare providers, 3) Alternative medicines were perceived to be highly effective, and 4) Religiosity and family elders played key roles in herbal use.

Conclusions

This study provides useful insights into perceptions and use of alternative treatments by patients that can be used by healthcare providers in developing appropriate interventions to encourage proper use of prescription medicines and alternative medicines resulting in improved management of these chronic diseases.

Introduction

The World Health Organization (WHO) reports that Type 2 Diabetes Mellitus (T2DM) and Hypertension (HTN) are two of the top ten causes of death among the Jamaican population [1]. Worldwide, the prevalence of diabetes has increased significantly since 1995 with over 48 million people currently living with the disease. In Jamaica, it is projected that there will be an additional 33,000 people diagnosed with diabetes by the year 2030, with the current prevalence being at over 200,000 cases [2]. Jamaica’s population is approximately 2.7 million people, and non-communicable diseases (NCDs) have increased the economic burden due to the working population being the most affected and decreasing productivity [3].

Complementary and alternative medicine (CAM) has been used for centuries across the globe and consist of a diverse subset of therapies such as dietary supplements, botanicals, traditional Chinese medicine, acupuncture, mind-body medicine, and therapeutic massage [1, 4, 5]. According to the World Health Organization, roughly 80% of the world’s population use at least one form of CAM [6]. Reasons for CAM use vary by country and level of conventional healthcare available among the populations [6]. In countries where many individuals lack access to healthcare resources, and with increasing healthcare costs globally, CAM can often provide a more affordable and accessible alternative to conventional medical care [5]. In high income countries such as the United States of America, CAM use deviates from traditional practices and has been adopted from other countries where CAM consumption is within the dominant structure of healthcare. Types of CAM used in the Caribbean are often methods that have been practiced for generations and have deep cultural and/or religious roots [7]. A survey that examined the use of herbal remedies among rural and urban Jamaicans of varying socioeconomic groups found that 100% of the participants used herbs [8].

Other research suggests that there are significant associations with herbal use and education, gender, religion, and health insurance status among Jamaicans [9]. It has also been shown that the use of herbal medicines in conjunction with prescription medications is common. Jamaicans are likely to use herbal medicine not only for the treatment of HTN and T2DM but also for illnesses such as the common cold, headache, or diarrhea [9]. In Jamaica and the United States, cases of HTN and T2DM are linked to lifestyle practices; however, it is evident that adherence to prescription medications for chronic diseases is lower for those living in the Caribbean compared to the United States [10].

This mixed-methods research study was conducted to provide a deeper understanding of CAM use for HTN and T2DM among Jamaicans. With the expected increase in T2DM and HTN, understanding the beliefs and use of alternative treatments is essential for the appropriate guidance of patients for proper management of these chronic diseases. We investigated CAM use, beliefs regarding the effectiveness of prescription medication and CAM, and discussion of CAM with healthcare providers (HCPs) by patients. The qualitative portion of the study provided an opportunity for open narratives and richer context within our target population.

Material and methods

Study design, site, and study population

A cross-sectional mixed-methods study was conducted from May to August 2018 in which convenience sampling was used to recruit patients ≥18 years of age attending clinics for HTN and T2DM in the four parishes of western Jamaica (St. James, Westmoreland, Hanover, and Trelawny) under the Western Regional Health Authority (WRHA). An exploratory design was used for the quantitative portion of the study among 60 participants [11]. Prior studies suggest the sample size (N = 60) is sufficient since the exploratory nature of the quantitative survey is the first stage of data collection and provides a rationale for defining future hypotheses for other stages of study [12]. In the concurrent quantitative-qualitative design, a smaller qualitative data design sample (N = 25) was determined as sufficient [11]. Clinic nurses informed patients of the study when they came in for an appointment. Patients who indicated interest to participate were introduced to the research team who told them about the study in private rooms in the clinic. After the potential participants were allowed to read the consent form, ask questions, and were satisfied that they wanted to participate, they were asked to sign the informed consent. At recruitment, participants were asked if they would be able to participate in a FGD session that would be arranged for a later date. Those who said that they could were asked to give their phone numbers to be contacted. Twenty-five participants completed the FGD sessions. Focus group participants were not allowed to complete the quantitative survey. Sixty participants completed the quantitative study.

Inclusion and exclusion criteria

Participants in this study were adults (≥18 years of age) who had been diagnosed with HTN and/or T2DM and were attending health clinics located in one of the four parishes under the WRHA. Those who did not meet these criteria were excluded.

Development of survey, focus group discussion guide and data collection

A survey was developed to collect data on demographic factors (age, education, employment status, income, and residence), use and beliefs regarding the effectiveness of prescription medication for HTN and T2DM, use and beliefs regarding the effectiveness of CAM, concomitant use of prescription medicine and CAM, and discussion of CAM with HCPs. Questions on knowledge, use and beliefs of CAM, and concomitant use of CAM with prescription medicines were adapted from questions used in published papers on studies conducted on CAM in Jamaica and Trinidad and Tobago [6, 8, 9, 13]. Questions were added to allow participants to list the types of CAM and the main herbal medicines they were using for HTN or T2DM. The survey was reviewed by Jamaican HCPs and revised. It was then pilot tested among 10 clinic patients in Jamaica similar to the ones recruited for the study and again revised before use. Other validation methods were not conducted. Surveys took approximately 30–45 minutes to complete.

Questions on the FGD guide were adapted from pertinent questions on the survey to generate discussion on the use of CAM, perception of the effectiveness of CAM and prescription medication, concurrent use of prescription medication and CAM, and communication with HCPs regarding medicinal practices. Five FGD sessions (two in St. James and one in each of the other three parishes) were conducted with 25 participants (three with 5, one with 4 and one with 6 participants). Participants who indicated that they could participate in a FGD session and gave their telephone numbers at recruitment were contacted with the date and time that the FGD session would be held. FGD sessions were conducted in vacant conference and exam rooms at the clinics. Each FGD session lasted approximately 75 minutes and was comprised of male and female participants who had HTN, T2DM, or both. Demographic information was obtained for each participant and FGD questions were tailored to generate discussion on when participants chose to use CAM, their perception of the effectiveness of CAM versus prescription medication, whether participants used prescription medication and CAM concurrently, and communication with their HCPs regarding their medicinal practices.

Ethical approval

The study was approved by the Institutional Review Board at the University of Alabama at Birmingham and by the Western Regional Health Authority; protocol approval #IRB-170310006.

Data analysis

Quantitative data

The quantitative data for the 60 survey respondents were entered into excel and imported into JMP Pro 14.0 for analysis. Descriptive statistics were used to describe demographic characteristics of participants using mean ± standard deviation for continuous variables and frequency (percentage) for categorical variables. Demographic characteristics between disease groups were compared using a Fisher’s Exact test for categorical characteristics, and an analysis of variance for continuous characteristics. The significance level for these comparisons was set at p≤0.05.

Qualitative data

Transcripts from the five FGD sessions were reviewed by three independent coders (SJN, LW, and OA) and coded using QSR International’s NVivo 11.4.3 software using line-by-line coding of all responses to the FGD questions, followed by focused coding for directed codes. We utilized constant comparative method to generate themes from the transcribed data [11]. Trustworthiness was achieved through data triangulation and peer debriefing [14]. Themes are presented in a manner that convey understanding of CAM and prescription medication use.

Results

Quantitative results

Demographic characteristics of survey participants

Sixty participants, aged 35–82 years, completed the survey; of those 60, 37 (61.7%) had HTN only, 10 (16.7%) had T2DM only, and 13 (21.7%) had both diseases (Table 1). On average, patients were 59.5 years; most were female (75%), had a secondary education (55%), had no income (28.8%), or were earning <J$24,800 a month (30.5%) (USD 1 = JD 122 at the time of the study; Table 1). Marital status was significantly associated with disease group, p = 0.0234; all other demographic characteristics did not significantly differ by disease group, all p>0.05, Table 1.

Table 1. Demographic characteristics of survey participants by disease group.
Total (N = 60) T2DM (N = 10) HTN (N = 37) HTN+T2DM (N = 13) p-value
Characteristic
Age, Mean (SD) years 59.5 (11.2) 62.3 (11.0) 59 (11.4) 58.8 (11.2) 0.6920d
Sex, N(%) 0.4874
    Male 15 (25.0) 4.0 (40.0) 8.0 (21.6) 3.0 (23.1)
    Female 45 (75.0) 6.0 (60.0) 29.0 (78.4) 10.0 (76.9)
Marital Status, N(%) 0.0234
    Marrieda 29 (41.7) 8.0 (80.0) 10.0 (27.0) 7.0 (53.8)
    Single 25 (10.0) 2.0 (20.0) 21.0 (56.8) 6.0 (46.2)
    Otherb 6 (48.3) 0.0 (0.0) 6.0 (16.2) 0.0 (0.0)
Education, N(%) 0.3911
    None 4 (6.7) 1.0 (10.0) 3.0 (8.1) 0.0 (0.0)
    Some/Complete Primary 20 (33.3) 3.0 (30.0) 11.0 (29.7) 6.0 (46.2)
    Some/Complete Secondary 33 (55.0) 6.0 (60.0) 22.0 (59.5) 5.0 (38.5)
    College/University 3 (5.0) 0.0 (0.0) 1.0 (2.7) 2.0 (15.4)
Parish, N(%) 0.6677
    Hanover 15 (25.0) 2.0 (20.0) 9.0 (24.3) 4.0 (30.8)
    St. James 12 (20.0) 4.0 (40.0) 5.0 (13.5) 3.0 (23.1)
    Trelawny 14 (23.3) 2.0 (20.0) 9.0 (24.3) 3.0 (23.1)
    Westmoreland 19 (31.7) 2.0 (20.0) 14.0 (37.8) 3.0 (23.1)
Incomec, N(%) 0.6466
    None 17 (28.8) 3.0 (30.0) 8.0 (22.2) 6.0 (46.2)
    <J$24,800 18 (30.5) 3.0 (30.0) 13.0 (36.1) 2.0 (15.4)
    J$24,801-J$60,000 16 (27.1) 2.0 (20.0) 11.0 (30.6) 3.0 (23.1)
    >J$60,000 8 (13.6) 2.0 (20.0) 4.0 (11.1) 2.0 (15.4)

HTN = Hypertension, T2DM = Type 2 Diabetes Mellitus.

a Includes Common Law marriage

b Other includes divorced, widowed and separated

c One participant declined to comment

d Analysis of Variance. Fisher’s Exact p-values for all categorical variables; p-value ≤0.05 considered meaningful.

Practices and beliefs regarding prescription medication use for T2DM and HTN (Table 2)

Table 2. Practices regarding prescription medication usage by survey participants.
T2DM (N = 10) HTN (N = 37) HTN+T2DM (N = 13) p-value
Survey Question, N (%)
When were you diagnosed with T2DM/HTN? 0.1780
    ≤10 years ago 3.0 (30.0) 19.0 (51.4) 3.0 (23.1)
    >10 years ago 7.0 (70.0) 18.0 (48.6) 10.0 (76.9)
Are you currently using any alternative treatments/home remedies for T2DM/HTN? 0.6237
    Yes 10.0 (100.0) 36.0 (97.3) 12.0 (92.3)
    No 0.0 (0.0) 1.0 (2.7) 1.0 (7.7)
Are you currently on medication from the clinic or doctor for your T2DM/HTN? 0.4006
    Yes 9.0 (90.0) 32.0 (86.5) 13.0 (100.0)
    No 1.0 (10.0) 5.0 (13.5) 0.0 (0.0)
Do you have difficulty picking up your T2DM/HTN medicine? 0.4768
    Yes 1.0 (10.0) 11.0 (33.3) 3.0 (23.1)
    No 8.0 (80.0) 20.0 (60.6) 10.0 (76.9)
    Sometimes 1.0 (10.0) 2.0 (6.1) 0.0 (0.0)
Do you get your T2DM/HTN medication free of cost? 0.0503
    Yes 4.0 (44.4) 23.0 (71.9) 12.0 (92.3)
    No 5.0 (55.6) 9.0 (28.1) 1.0 (7.7)
How much do you pay for your T2DM/HTN medicine? 0.1633
    <J$2000 1.0 (12.5) 3.0 (17.7) 3.0 (37.5)
    J$2000-J$4999 6.0 (75.0) 8.0 (47.1) 1.0 (12.5)
    ≥J$5000 1.0 (12.5) 6.0 (35.3) 4.0 (50.0)
Do you refill your T2DM/HTN medication on time? 0.4366
    Yes 9.0 (90.0) 23.0 (71.9) 12.0 (92.3)
    No 0.0 (0.0) 6.0 (18.8) 1.0 (7.7)
    Sometimes 1.0 (10.0) 3.0 (9.4) 0.0 (0.0)
Do you always take your T2DM/HTN medicine(s) as prescribed? 0.1795
    Yes 6.0 (60.0) 22.0 (68.8) 9.0 (69.2)
    No 2.0 (20.0) 10.0 (31.2) 3.0 (23.1)
    Sometimes 2.0 (20.0) 0.0 (0.0) 1.0 (7.7)
Do you experience any side effects from your T2DM/HTN medicine(s)? 0.9999
    Yes 4.0 (40.0) 15.0 (46.9) 6.0 (46.2)
    No 6.0 (60.0) 17.0 (53.1) 7.0 (53.8)
If you get a normal blood pressure reading, do you stop taking your prescription medication? 0.9999
    Yes NA 6 (18.7) 10 (77.0)
    No NA 26 (81.3) 3 (23.0)
Does a normal BP (120/80) mean that: 0.7037
    You are cured NA 1 (2.7) 0 (0.0)
    Your blood pressure is normal at the time but you still have high blood pressure. NA 36 (97.3) 13 (100.0)

Fisher’s Exact p-values; p ≤ 0.05 considered meaningful. HTN = Hypertension; T2DM = Type 2 Diabetes Mellitus.

There were no significant associations among disease groups and survey responses, all p>0.05 (Table 2). More than half of participants (58.3%) had been diagnosed with T2DM or HTN for over 10 years and all but two (1 with HTN; 1 with HTN+T2DM) reported using CAM (Table 2). The most common CAM method used was herbal medicine; this was followed in sequential order by exercise, spiritual healing, relaxation techniques, and diet modifications.

Most participants (90% with T2DM, 86.5% with HTN, and 100% with HTN+T2DM) were on prescription medication for their condition and most received their medication from a pharmacy at a health center or a private pharmacy (Table 2). Most participants (73.3%) reported filling their prescriptions on time. The main difficulties participants reported that they experienced in picking up their prescriptions were financial difficulty, issues with their government-issued insurance card, the pharmacy being out of medication, transportation issues, and need for someone to pick up the medication. T2DM (44.4%), HTN (71.9%) participants and those with both conditions (92.3%) reported getting their medication free of cost.

Participants with T2DM (60%), HTN (68.8%), and both conditions (69.2%) reported taking their medication as prescribed. Side effects, substitution/preference of alternate medication, forgetting to take, and stopping to see if the medication was working were the main reasons given by participants for not taking their medication as prescribed. Seventy-three percent of participants felt that their prescription medication was controlling their condition; most of those who felt the medication was not controlling their condition said that the medication was not effective enough. The most common side effects reported by participants with T2DM were itchiness, stomach pains, and increased urination and by participants with HTN were dizziness, headache, nausea/stomachache, muscle pain, and increased urination. The majority of participants with HTN (97.3%) and both HTN and T2DM (100%) knew that a blood pressure reading of 120/80 did not mean that they were cured or that they should stop taking their prescription medication.

Table 3 shows the total number of participants who selected each herb as well as the total numbers stratified by disease group. The top five herbs listed by participants with T2DM were guinea hen (Petiveria alliacea), moringa (Moringa oleifera), garlic (Allium sativum), ginger (Zingiber officinale), and turmeric (Curcuma longa). Participants with HTN listed garlic, moringa, guinea hen, lime (Citrus aurantiifolia), and ginger as their top five and those with both T2DM and HTN listed turmeric, moringa, ginger, lime, and garlic.

Table 3. Total number of participants who selected each herb and total numbers stratified by disease group.

Herbs listed by highest percentage of total.

Top six herbs listed by participants Total (N = 60) Type 2 Diabetes Mellitus (N = 10) Hypertension (N = 37) T2 Diabetes Mellitus and Hypertension (N = 13)
N (%) N (%) N (%) N (%)
Guinea Hen 20 (33.3) 8 (80.0) 10 (27.0) 2 (15.4)
Moringa 20 (33.3) 5 (50.0) 11 (29.7) 4 (30.8)
Garlic 32 (53.3) 3 (30.0) 26 (70.3) 3 (23.1)
Ginger 13 (21.7) 3 (30.0) 6 (16.2) 4 (30.1)
Turmeric 12 (20.0) 3 (30.0) 4 (10.8) 5 (38.5)
Lime 11 (18.3) 0 (0.0) 7 (18.9) 4 (30.8)

Other herbs listed include were lemon grass/fever grass (Cymbopogon citratus), cerasse (Momordica charantia), mint (mentha), cinnamon (Cinnamomum verum), soursop leaves (Annona muricata), coconut water (Cocos nucifera), ganja (Cannabis), breadfruit leaves (Artocarpus altilis), rosemary (Salvia Rosmarinus), vervain (Verbena officinalis) and neem (Azadirachta indica).

Knowledge, attitudes, and practices regarding CAM use by disease group (Table 4)

Table 4. Knowledge, attitudes, and practices regarding CAM use by disease group.
T2DM (N = 10) HTN (N = 37) HTN+T2DM (N = 13) p-value
Survey Question, N (%)
Do you think herbal medicines control your T2DM/HTN? 0.8679
    Yes 7.0 (70.0) 22.0 (68.8) 11.0 (84.6)
    No 2.0 (20.0) 3.0 (9.4) 1.0 (7.7)
    Sometimes 1.0 (10.0) 6.0 (18.8) 1.0 (7.7)
    Unsure NA 1.0 (3.1) 0.0 (0.0)
When you use herbal medicine, do you still take your prescription medication as prescribed? 0.1174
    Yes 7.0 (70.0) 19.0 (57.6) 4.0 (33.3)
    No 3.0 (30.0) 14.0 (42.4) 6.0 (50.0)
    Sometimes 0.0 (0.0) 0.0 (0.0) 2.0 (16.7)
Have you received information about alternative treatments? 0.2074
    Yes 10.0 (100.0) 31.0 (83.8) 13.0 (100.0)
    No 0.0 (0.0) 6.0 (16.2) 0.0 (0.0)
Where or from whom did you receive the information? 0.8447
    Word of Mouth 6 (60.0) 20 (66.6) 11 (84.6)
    Internet, Television, or Radio 2 (20.0) 6 (20.0) 2 (3.8)
    Own Research 1 (10.0) 2 (6.7) 0 (0.0)
    Health Provider 1 (10.0) 2 (6.7) 0 (0.0)
Have you discussed alternative treatments for T2DM/HTN with your healthcare provider? 0.1553
    Yes 1.0 (10.0) 9.0 (24.3) 6.0 (46.2)
    No 9.0 (90.0) 28.0 (75.7) 7.0 (53.8)
Do you take alternate treatments when you cannot afford your prescribed medications? 0.7336
    Yes 2.0 (20.0) 9.0 (25.7) 4.0 (30.8)
    No 7.0 (70.0) 25.0 (71.4) 8.0 (61.5)
    Sometimes 1.0 (10.0) 1.0 (2.9) 1.0 (7.7)
Do you experience any negative side effects when taking alternative medication? 0.7470
    Yes 0.0 (0.0) 3.0 (8.1) 0.0 (0.0)
    No 10.0 (100.0) 34.0 (91.9) 13.0 (100.0)
Are there any possible harmful effects of using both herbal and prescription medicines at the same time? 0.9174
    Yes 2.0 (20.0) 9.0 (27.3) 3.0 (23.1)
    No 8.0 (80.0) 20.0 (60.6) 9.0 (69.2)
    Unsure 0.0 (0.0) 4.0 (12.1) 1.0 (7.7)

Fisher’s Exact p-values; p ≤ 0.05 considered meaningful. HTN = Hypertension; T2DM = Type 2 Diabetes Mellitus.

Participants were asked to respond to a variety of questions related to their perceptions and behaviors regarding CAM use. Participant responses were not significantly associated with disease group, all p>0.05 (Table 4). Participants (73%) indicated that herbal medicines controlled their conditions. T2DM (30%), HTN (42.4%), and participants with both conditions (50%) reported that they do not take their prescription medication as prescribed when they take herbal medicines. The reasons given for not taking herbal and prescription medicines simultaneously were: did not want herbal medicine to interfere with prescription medicine, did not want to take too much medicine, preferred to use herbs, wanted to take less prescription medicine, wanted to see if herbs were more effective, and did not want blood pressure to drop too low. All of the diabetic participants and those with both conditions along with 84% of hypertensive participants reported that they had received information about CAM, mainly that CAM can help to control T2DM and HTN, can benefit and are good for the body, and can kill cancer cells. A few participants reported that they heard that herbs were not good for the body and can worsen symptoms. Most reported that they received information from family, friends, and community members; only small percentages (10% with T2DM, 24% with HTN, 46.2% with both conditions) reported discussing CAM with their HCPs. The main reasons participants gave for not discussing CAM with HCPs were: HCPs do not ask about CAM, they did not think of discussing CAM with HCPs, and HCPs do not approve of CAM. The top five reasons given in choosing to use CAM were: CAM helps to control blood sugar/blood pressure, others recommended CAM, CAM is used when they do not have their prescription medication, they wanted to try CAM, and CAM is preferred over prescription medication. About one-quarter of participants reported taking CAM once or twice daily and when they are experiencing symptoms or are unable to afford prescription medication. Over 90% of participants reported no negative side effects of CAM, a few reported sleepiness, dizziness, loss of balance, and sinus issues. Twenty percent of participants with T2DM, 27% with HTN, and 23.1% of those with both conditions felt that there were possible harmful effects of taking prescription medications and CAM simultaneously. Apart from general side effects such as stomachache and headache, a few participants felt that taking prescription medication and CAM simultaneously could lower blood sugar or blood pressure too much.

Participants’ beliefs regarding the use of prescription medications and CAM (Table 5)

Table 5. Perceptions and beliefs regarding use of alternative and prescription treatments by disease group.
T2DM (N = 10) HTN (N = 37) HTN+T2DM (N = 13) p-value
Survey Question, N (%)
Alternative treatments should always be used instead of prescription medication. 0.8835
    Yes 4.0 (40.0) 12.0 (32.4) 6.0 (46.2)
    No 4.0 (40.0) 16.0 (43.2) 6.0 (46.2)
    Sometimes 1.0 (10.0) 7.0 (18.9) 1.0 (7.7)
    Unsure 1.0 (10.0) 2.0 (5.4) 0.0 (0.0)
Alternative treatments are more effective at treating T2DM/HTN than prescription medication. 0.4118
    Yes 5.0 (50.0) 14.0 (37.8) 3.0 (23.1)
    No 3.0 (30.0) 19.0 (51.4) 7.0 (53.8)
    Sometimes 1.0 (10.0) 3.0 (8.1) 3.0 (23.1)
    Unsure 1.0 (10.0) 1.0 (2.7) 0.0 (0.0)
If you are experiencing unpleasant side effects of prescription medication, is it okay to stop taking the medicine without consulting your healthcare provider? 0.5566
    Yes 1.0 (10.0) 9.0 (24.3) 4.0 (30.8)
    No 9.0 (90.0) 28.0 (75.7) 8.0 (61.5)
Do you think it is okay to use both prescription medication and alternative treatments at the same time to treat T2DM/HTN? 0.1555
    Yes 3.0 (30.0) 4.0 (10.8) 4.0 (30.8)
    No 7.0 (70.0) 33.0 (89.2) 9.0 (69.2)
Do you think that you should always discuss any alternative treatments for your condition with your healthcare provider? 0.3763
    Yes 7.0 (70.0) 29.0 (78.4) 12.0 (92.3)
    No 3.0 (30.0) 8.0 (21.6) 1.0 (7.7)

Fisher’s Exact p-values; p ≤ 0.05 considered meaningful. HTN = Hypertension; T2DM = Type 2 Diabetes Mellitus.

The responses from a series of questions that evaluated participants’ beliefs regarding the use of prescription medication and CAM and using them simultaneously are presented in Table 5. No significant differences in beliefs about CAM by disease group were found, all p>0.05. Thirty-seven percent of participants believed that CAM should always be used instead of prescription medication and that CAM is the most effective form of treatment for their conditions. Seventy-five percent indicated that they would communicate negative side effects to their HCP before deciding to discontinue their prescription medications. A majority of participants (81.6%) did not believe that it was okay to use prescription and CAM at the same time and 80% believed that they should always discuss CAM use with their HCP.

Qualitative results

Four common themes emerged during FGD sessions (Table 6), which revealed the views and beliefs of participants regarding CAM and prescription medication use for chronic disease management.

Table 6. Focus group themes.

1) Simultaneous use of herbal and prescription medicine was perceived to be harmful.
2) Patients did not divulge their use of herbal medicine to healthcare providers.
3) Alternative medicines were perceived to be highly effective
4) Religiosity and family elders played key roles in herbal use.

Theme #1: Simultaneous use of herbal and prescription medicine was perceived to be harmful

With regard to the simultaneous use of prescription medications with herbal medicines, most participants indicated that simultaneous use would cause adverse health effects and that both should not be taken concomitantly. Some participants expressed the consequences of misusing these treatments, which include low blood pressure or low blood glucose and the possibility of losing consciousness. One participant expressed her personal and interpersonal experiences that summarized this theme:

I went to the clinic and someone told me to take it [garlic] like pill but don’t use it with the medication because it will knock you out because it happened to me once [meaning to the other person] -(Participant 2, Trelawny, Female)

When I used them at the same time it hit me out and sent me to the hospital and made the pressure very low, so I don’t use them together. -(Participant 2, Trelawny, Female)

Relating a similar experience, one participant discussed her regimen for taking prescription medication and herbs.

If I could get some herbs to take and see it helping the sugar and the pressure, I will leave the medication, but you cannot just come off it quick because it will physically hurt you. -(Participant 3, Trelawny, Female)

Theme #2: Patients did not divulge their use of herbal medicine to healthcare providers

Most participants conveyed that they did not feel it was necessary to communicate CAM use with their HCP. There was a perception of fear that the HCP would disagree with the patients’ decision to use CAM and advise against what was working for the patients. There were also indications that because herb use is an intricate part of the Caribbean culture, some herbs were used for other conditions, such as headaches or sinuses and without the intention of treating an individual’s HTN or T2DM. Therefore, participants did not think to inform their HCP. One participant stated,

I’m not discussing any herbs with the doctor because when you tell him about herbs he says ‘nonsense’, ‘foolishness’ so I continue to drink the herb. I put the medication aside for a while, go on the herb, and then back to the medication.(Participant 3, Trelawny, Female)

On the other hand, the depth of the HCP-patient relationship was also an indicator of whether a respondent felt comfortable with disclosing information about herb use. There were several physicians working at the clinics that were not originally from Jamaica, which influenced the communication a patient received about herb use.

My doctor is a Nigerian that supports both herbs and medication. I would love my Nigerian doctor to give me the herbs because I know he has an herb book and he knows which ones are best so I can get a list.(Participant 4, Trelawny, Female)

Theme #3: Alternative medicines were perceived to be highly effective

Most of our participants perceived CAM to be more effective than prescription medications due to the known possible side effects of prescription medication. They also believed that some prescription medication alleviated the chronic disease but caused other complications.

Yes, I believe the herb is coming from the spiritual background the medication the doctor gives is not as effective. I discovered that even the medication slows down your sex organ and the herb uplifts it.(Participant 23, St. James, Male)

I think so because a lot of the chemical treatment ends up damaging the body so I think more research should be done in the herbal area, a lot of doctors don’t support it because they won’t be getting money.—(Participant 5, St. James, Male)

One participant conveyed that although she was in favor of CAM, her prescription medication was equally as effective and provided her with rapid results. When the group was asked if they still take their prescription medication as prescribed when using herbal medications, one participant answered:

I live on my medication but I just take it (herb) for tea so I still take my [prescription] medication.(Participant 16, Westmoreland, Female)

Theme #4: Religiosity and family elders played key roles in herbal use

When participants were asked about how they were informed of CAM, most responded that their family and community elders influenced them and that they grew up witnessing people in their communities sharing CAM methods to treat a wide variety of illnesses. Also, many expressed listening to radio doctors explain CAM methods for certain conditions.

I learned a lot from my grandmother even when I had my children, she told me what type of herbs to give them.(Participant 11, Hanover, Female)

I heard from my parents my mother and father they said that the garlic is good for pressure.–(Participant 14, Hanover, Male)

I hear plenty people talk about the garlic plus a doctor I hear over the radio talks about garlic and says it is good.(Participant 1, Trelawny, Female)

Within each FGD session, participants expressed that religion played a role in their comfort with using CAM for chronic diseases and other illnesses. For instance, two participants responded:

God put herbs on the earth to heal people, but they are not using it because when I take the pill they give me a lot of side effects.(Participant 3, Trelawny, Female)

Herbal comes from my religion the Seventh-day Adventist, the prophetess, Ellen, tells us that herbs are good for the body—(Participant 23, Hanover, Male)

Discussion

Results from the quantitative and qualitative analysis mirror each other. Responses from our focus groups provided a better understanding of the societal beliefs that individuals have acquired and shed light on why some individuals prefer CAM methods, particularly herbal remedies, to prescription medication.

The survey revealed that a majority of our participants chose to use CAM because prescription medications had side effects that included headaches, decreased energy, and stomachaches. This theme was noted in our FGD sessions in which participants stated that the reduced or nonexistent side effects of CAM were preferred over side effects from prescription medicines. Participants also believed that since prescription medications were made from herbs they were the purest form of medication and best for the body. Studies conducted to understand the perceived risks and benefits of herbal use by participants, report that herbal use is not perceived as being safer than conventional medicines but are viewed as being more “natural” [15].

The majority of participants stated that they do not use herbal and prescription medicines together fearing that combined use will decrease their blood pressure or blood glucose to dangerous levels. Several randomized control trials have been conducted with different herbs and orthodox medications among both diabetic and hypertensive patients. Several trials have shown that garlic significantly lowered both systolic and diastolic blood pressure among patients who were administered garlic (extract or powder at concentrations of 240–960 mg/day) plus antihypertensive drugs or diuretics compared to those administered placebo plus antihypertensive drugs or diuretics [16, 17]. No serious adverse events were reported from the use of garlic and prescription medicines in these studies. Garlic was also found to significantly reduce the level of fasting blood glucose in T2DM patients in several randomized control trials of patients treated with garlic and anti-diabetic drugs compared to control groups [1821]. In these studies, significant improvements in total blood cholesterol, high density lipoprotein and low-density lipoprotein were also obtained after garlic administration. Heartburn was reported by some patients but was not significantly different between the treated and control groups.

In a clinical trial with ginger, one gram of ginger was shown to work synergistically with Nifedipine (10 mg daily) in inhibiting platelet aggregation in hypertensive patients. This shows that addition of ginger to hypertensive medicine was beneficial for cardiovascular and cerebrovascular complication due to platelet aggregation [22]. No adverse effect of ginger was reported. However, studies of other herbs indicate that concomitant use with prescription medications may cause adverse reactions. Several studies reviewed by Izzo et al. (2005) showed adverse reactions between cardiovascular drugs such as warfarin and a number of herbs including garlic and ginkgo resulting in increased anticoagulation and with a number of other herbs such as ginseng and green tea causing decreased anticoagulation [2327].

Consistent with other studies, our study participants also believed it is important to communicate their use of CAM with their HCPs, although they chose not to disclose CAM use due to fear of disapproval [8]. A study reported that HCPs do not have adequate knowledge of CAM use, and thus are not able to give medical advice to patients who use CAM [28]. This may in part explain HCPs’ reluctance in discussing CAM use with patients. Moreover, literature also suggests that HCPs want to understand the use of CAM and the case-based research behind its use [29]. Therefore, changes to the curriculum for medical, nursing, dietetic and pharmacy students, residents, and fellows to include CAM methods may facilitate increased knowledge of the beneficial and harmful effects of CAM. A finding of interest was that nationality and cultural background of HCPs may influence how information on CAM methods is translated to the public. A participant discussed her interactions with a HCP of African nationality who she is convinced has good knowledge of herbs. Studies conducted in Trinidad and Tobago and Jamaica found a higher level of acceptance of CAM use among Trinidadian HCPs in comparison to those from Jamaica; however, HCPs in both countries seemed to lack proper knowledge about herb-drug use interactions that could be contributing to the lack of communication with patients [8].

Previous research suggests that there should be increased efforts aimed to increase information on the possible harmful effects of concurrent herb use with prescription drugs [6].

Religion was an important factor in influencing herbal use in this study. Therefore, clergy members could be used in conjunction with HCPs to relay pertinent information regarding CAM use. Recent studies show that clergy members are key components in health promotion [30].

Limitations

This study has limitations that should be considered in interpreting the results. First, the convenience sampling method used is prone to inherent bias in representation. Some patients declined to participate in the study due to lack of trust in providing personal health information to the research staff; they feared that the personal information provided could be used against them. Secondly, the study sample represents only patients who attended the chronic disease clinics in the WRHA that were included in the study, therefore, the results may not be generalizable to patients attending other clinics under the WRHA or in other regions of Jamaica that were not sampled. Additionally, the data were self-reported and as a result might be subject to social desirability bias.

Conclusions

This study shows that CAM methods such as use of herbs, prayer, diet, and exercise to treat chronic diseases are a part of daily life for many Jamaicans. The findings from the survey and the themes from the FGD sessions provided new information and useful insights into the perceptions of participants regarding their inclination to use CAM. Participants believed based on their own personal experiences, and those of community/church members, that alternative treatments are effective with far less adverse effects as compared to prescription medicine. They did not discuss CAM use with their HCPs since they felt that most HCPs did not endorse the use of CAM. These findings highlight the importance of HCP-initiated conversations about patient use of CAM. Many participants are aware that there could be adverse reactions to the concurrent use of prescription and herbal treatments and developed their own algorithms of use which could be harmful. Thorough explanations of the effects of simultaneous or intermittent use of prescription and herbal treatments from knowledgeable HCPs is essential. Thus, the findings from this study indicate the need to include salient information on CAM in the professional curricula of HCPs and can be used in developing appropriate interventions to ensure the proper use of prescription medicines and CAM. This should result in improved management of T2DM and HTN among patients.

Supporting information

S1 Dataset. CAM dataset HTN & T2DM Jamaica.

(XLSX)

S1 File. Survey used in study.

(PDF)

S2 File. Focus group discussion guide.

(DOCX)

Acknowledgments

We thank the nurses in the clinics who facilitated the study and the patients who participated.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This study was supported by the Minority Health International Research Training (MHIRT) grant no. T37-MD001448 from the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), Bethesda, Maryland, USA, and the Western Regional Health Authority, Ministry of Health, Jamaica.

References

  • 1.World Health Organization. Jamaica. 2018 [Cited 7 July 2020]. [Internet]. Available from: www.who.int/nmh/countries/jam_en.pdf?ua=1.
  • 2.Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004. May;27(5):1047–53. 10.2337/diacare.27.5.1047 [DOI] [PubMed] [Google Scholar]
  • 3.Ferguson TS, Tulloch-Reid MK, Wilks RJ. The epidemiology of diabetes mellitus in Jamaica and the Caribbean: a historical review. West Indian Med J. 2010. June;59(3):259–64. [PubMed] [Google Scholar]
  • 4.World Health Organization. Traditional, Complementary and Integrative Medicine. [Cited 7 July 2020]. In: World Health Organization [Internet]. Available from: https://www.who.int/health-topics/traditional-complementary-and-integrative-medicine#tab=tab_1.
  • 5.World Health Organization. WHO Traditional Medicine Strategy 2014–2023. 2013 [cited 2020 July 7]. Available from: https://apps.who.int/iris/handle/10665/92455.
  • 6.Clement YN, Williams AF, Khan K, Bernard T, Bhola S, Fortuné M, et al. A gap between acceptance and knowledge of herbal remedies by physicians: the need for educational intervention. BMC Complement Altern Med. 2005. November 18;5:20 10.1186/1472-6882-5-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Bahall M, Edwards M. Perceptions of complementary and alternative medicine among cardiac patients in South Trinidad: a qualitative study. BMC Complement Altern Med. 2015;15:99 10.1186/s12906-015-0577-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Delgoda R, Younger N, Barrett C, Braithwaite J, Davis D. The Prevalence of Herbs Use in Conjunction with Conventional Medicines in Jamaica. Complement Ther Med. 2010. February;18(1):13–20. 10.1016/j.ctim.2010.01.002 [DOI] [PubMed] [Google Scholar]
  • 9.Picking D, Younger N, Mitchell S, Delgoda R. The prevalence of herbal medicine home use and concomitant use with pharmaceutical medicines in Jamaica. J Ethnopharmacol. 2011. September 1;137(1):305–11. 10.1016/j.jep.2011.05.025 [DOI] [PubMed] [Google Scholar]
  • 10.Boume PA, McGrowder DA. Health status of patients with self-reported chronic diseases in Jamaica. N Am J Med Sci. 2009. December;1(7):356–64. 10.4297/najms.2009.7356 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Creswell JW, Clark VLP. Designing and conducting mixed methods research. 3rd edition SAGE Publications, Inc; 2018. [Google Scholar]
  • 12.Kutner JS, Steiner JF, Corbett KK, Jahnigen DW, Barton PL. Information needs in terminal illness. Soc Sci Med. 1999;48(10):1341–1352. 10.1016/s0277-9536(98)00453-5 [DOI] [PubMed] [Google Scholar]
  • 13.Bahall M, Legall G. Knowledge, attitudes, and practices among health care providers regarding complementary and alternative medicine in Trinidad and Tobago. BMC Complement Altern Med. 2017;17(1):144 Published 2017 Mar 8. 10.1186/s12906-017-1654-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Shenton AK. Strategies for ensuring trustworthiness in qualitative research projects. Education for information. 2004;22(2):63–75. [Google Scholar]
  • 15.Lynch N, Berry D. Differences in perceived risks and benefits of herbal, over-the-counter conventional, and prescribed conventional, medicines, and the implications of this for the safe and effective use of herbal products. Complement Ther Med. 2007. June;15(2):84–91. 10.1016/j.ctim.2006.06.007 [DOI] [PubMed] [Google Scholar]
  • 16.Ried K, Frank OR, Stocks NP. Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomised controlled trial. Maturitas. 2010;67(2):144–50. 10.1016/j.maturitas.2010.06.001 [DOI] [PubMed] [Google Scholar]
  • 17.Ried K, Frank OR, Stocks NP. Aged garlic extract reduces blood pressure in hypertensives: a dose-response trial. Eur J Clin Nutr. 2013;67(1):64–70. 10.1038/ejcn.2012.178 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Sobenin IA, Nedosugova LV, Filatova LV, Balabolkin MI, Gorchakova TV, Orekhov AN. Metabolic effects of time-released garlic powder tablets in type 2 diabetes mellitus: the results of double-blinded placebo-controlled study. Acta Diabetol. 2008;45(1):1–6. 10.1007/s00592-007-0011-x [DOI] [PubMed] [Google Scholar]
  • 19.Ashraf R, Phil M, Khan RA, Ashraf I. Effects of garlic on blood glucose levels and HbA1c in patients with type 2 diabetes mellitus. Journal of Medicinal Plants Research. 2011;5:2922–8. [Google Scholar]
  • 20.Chhatwal S, Sharma RK, Sharma G, Khurana A. To study the antihyperglycaemic and lipid lowering effect of garlic as an adjunct to metformin in patients of type 2 diabetes mellitus with obesity. International Journal of Basic & Clinical Pharmacology. 2017;1(1):5. [Google Scholar]
  • 21.Manafikhi R, Kalie L, Lahdo R. Effects of Garlic Supplementation on Fasting Blood Sugar, HbA1c and Lipid Profile in Type 2 Diabetics Receiving Metformin and Glyburide. International Journal of Academic Scientific Research. 2015;3(2):11–8. [Google Scholar]
  • 22.Young HY, Liao JC, Chang YS, Luo YL, Lu MC, Peng WH. Synergistic effect of ginger and nifedipine on human platelet aggregation: a study in hypertensive patients and normal volunteers. Am J Chin Med. 2006;34(4):545–51. 10.1142/S0192415X06004089 [DOI] [PubMed] [Google Scholar]
  • 23.Sunter W. Warfarin and garlic. Pharm J. 1991;246(722.1991). [Google Scholar]
  • 24.Matthews MK Jr. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology. 1998;50(6):1933–4. 10.1212/wnl.50.6.1933 [DOI] [PubMed] [Google Scholar]
  • 25.Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol. 2005;98(1):1–14. 10.1016/j.ijcard.2003.06.039 [DOI] [PubMed] [Google Scholar]
  • 26.Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm. 1997;54(6):692–3. 10.1093/ajhp/54.6.692 [DOI] [PubMed] [Google Scholar]
  • 27.Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother. 1999;33(4):426–8. 10.1345/aph.18238 [DOI] [PubMed] [Google Scholar]
  • 28.Milden SP, Stokols D. Physicians' attitudes and practices regarding complementary and alternative medicine. Behav Med. 2004. Summer;30(2):73–82. 10.3200/BMED.30.2.73-84 [DOI] [PubMed] [Google Scholar]
  • 29.Patel SJ, Kemper KJ, Kitzmiller JP. Physician perspectives on education, training, and implementation of complementary and alternative medicine. Adv Med Educ Pract. 2017. July 25;8:499–503. 10.2147/AMEP.S138572 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Bopp M, Baruth M, Peterson JA, Webb BL. Leading their flocks to health? Clergy health and the role of clergy in faith-based health promotion interventions. Fam Community Health. 2013. Jul-Sep;36(3):182–92. 10.1097/FCH.0b013e31828e671c [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Jenny Wilkinson

26 Aug 2020

PONE-D-20-21696

The Use of Complementary and Alternative Medicine among Hypertensive and Type 2 Diabetic Patients in Western Jamaica: A Mixed Methods Study

PLOS ONE

Dear Dr. Jolly,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 10 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Jenny Wilkinson, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please address the following:

- Please include additional information regarding the interview guide and questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. With regards to the questionnaire, please also provide further details concerning the development and validation of this tool.

- Please ensure you have discussed how the sample size was determined for the quantitative arm of this study, for example following a sample size calculation.

3.We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Additional Editor Comments (if provided):

Thank you for your submission, reviewers have provided comments and I now invite you to respond to these comments. I draw your attention particularly to the comments in relation to the methods and results as addressing these items will strengthen your work. Appropriate inferential statistic should be included in the data analysis.

In addition, please ensure that scientific names are given for all herbs that are mentioned and that capitalisation of drug and plant names are appropriate (i.e. capitals for trade names and lower case for common names of plants/herbs).

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: i think this research does a good job highlighting the prevalent use of nontraditional medicines in the management of chronic health conditions and the importance of more explicit exploration of usage by patients on the part of health care providers. where is the data reporting on the different types of CAM being used by the surveyed patients? of course, the focus was obviously on the use of of herbal supplements/foods as representative of CAM (there is passing mention of exercise, spiritual healing, relaxation techniques, diet modification). the paragraph that begins at line 76 seems unnecessary.

Reviewer #2: i. The manuscript somehow sound, though some information not presented, e.g. sample size, sampling techniques and procedures, and the data may support the conclusion after addressing the comments. Also, to much limitations while some of them are in the Author’s control.

ii. The author didn’t indicate the statistical analysis program used to analyze the quantintaive data.

iii. The author is not ready to make the data available freely, some restrictions will apply

iv. The manuscript presented in an intelligible fashion, but some sentences are not clearly explained, so need some improvements in language.

v. Research ethics are already considered

vi. Other comments found in the manuscript attached to this document.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-20-21696_reviewer.pdf

PLoS One. 2021 Feb 8;16(2):e0245163. doi: 10.1371/journal.pone.0245163.r002

Author response to Decision Letter 0


3 Nov 2020

November 2, 2020

RE: PONE-D-20-21696

The Use of Complementary and Alternative Medicine among Hypertensive and Type 2 Diabetic Patients in Western Jamaica: A Mixed Methods Study

Dear Editor,

Thank you for sending the comments from the reviewers of our paper submitted to PLOS ONE. We have made the corrections requested and have attached the revised paper with highlights and a clean version for further consideration. We thank the reviewers for their careful review and believe that the changes have significantly improved the quality of the manuscript. This is a point-by-point response detailing the revisions that have been made and highlighted in the manuscript.

Journal Requirements:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: We have reviewed the style templates to ensure that the manuscript meets PLOS ONE's style requirements, including those for file naming.

2. Please include additional information regarding the interview guide and questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. With regards to the questionnaire, please also provide further details concerning the development and validation of this tool. Please ensure you have discussed how the sample size was determined for the quantitative arm of this study, for example following a sample size calculation.

Response: We have added detailed information regarding development of the focus group interview guide and the questionnaire used in the study on pages 6-7 and have included a copy of each, in English (the original language) as Supporting Information. The quantitative results serve as evidence for hypothesis generation for future studies. Therefore, our participant sample size (N=60) is sufficient.

3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide.

Response: a) b) There are no ethical or legal restrictions on sharing a de-identified data set. The anonymized data set has been uploaded as a Supporting file titled “S1_Dataset.xlsx” with our revised submission

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Response: We have included captions for the Supporting Information files at the end of the manuscript and have updated in-text citations to match accordingly.

Additional Editor Comments:

Thank you for your submission, reviewers have provided comments and I now invite you to respond to these comments. I draw your attention particularly to the comments in relation to the methods and results as addressing these items will strengthen your work. Appropriate inferential statistic should be included in the data analysis.

Response: We have addressed the comments related to the methods and results that strengthen the paper. Appropriate inferential statistics have been included in the data analysis and the new results presented in Tables 1-4. The text of the quantitative results has been revised accordingly.

In addition, please ensure that scientific names are given for all herbs that are mentioned and that capitalization of drug and plant names are appropriate (i.e. capitals for trade names and lower case for common names of plants/herbs).

Response: This has been done.

5. Review Comments to the Author

Reviewer #1:

i. I think this research does a good job highlighting the prevalent use of nontraditional medicines in the management of chronic health conditions and the importance of more explicit exploration of usage by patients on the part of health care providers. Where is the data reporting on the different types of CAM being used by the surveyed patients? of course, the focus was obviously on the use of herbal supplements/foods as representative of CAM (there is passing mention of exercise, spiritual healing, relaxation techniques, diet modification).

Response: We agree with the reviewer that the focus of the study was the use of herbal treatments. We do provide information on the sequential order of the different types of CAM used by the patients, i.e. herbal medicine followed by exercise, spiritual healing, relaxation techniques and diet modification on page 10 of the manuscript. We did not conduct further investigation into these different types of CAM in this study.

ii. The paragraph that begins at line 76 seems unnecessary.

Response: We agree with the reviewer and have deleted the paragraph.

Reviewer #2:

i. The manuscript somehow sound, though some information not presented, e.g. sample size, sampling techniques and procedures, and the data may support the conclusion after addressing the comments.

Response: We have added details on the convenience sampling method and procedures used in the study on pages 5-6 of the manuscript. We have explained that the quantitative study was designed to collect data to serve as evidence for hypothesis generation for future studies. Therefore, a sample size of 60 participants was considered sufficient.

ii. Also, too much limitations while some of them are in the Author’s control.

Response: We thank the reviewer and have revised the limitations.

iii. The author didn’t indicate the statistical analysis program used to analyze the quantitative data.

Response: The statistical analysis method has been added to the paper as stated below. “The questionnaire data for the 60 participants were entered into excel and imported into JMP Pro 14.0 for analysis. Descriptive statistics were used to describe demographic characteristics of participants using mean ± standard deviation for continuous variables and frequency (percentage) for categorical variables. Demographic characteristics between disease groups were compared using a Fisher’s Exact test for categorical characteristics, and an analysis of variance for continuous characteristics. The significance level for these comparisons was set at p ≤0.05.”

iv. The author is not ready to make the data available freely, some restrictions will apply

Response: We have uploaded the dataset as a supporting file labeled “S1_Dataset.xlsx”.

v. The manuscript presented in an intelligible fashion, but some sentences are not clearly explained, so need some improvements in language.

Response: The manuscript has been revised thoroughly to clarify statements and improve the language.

vi. Research ethics are already considered

Response: Thank you.

vii. Other comments found in the manuscript attached to this document.

Response: We have addressed all of the comments in the manuscript.

Thank you for your kind consideration.

Respectfully,

Pauline Jolly, PhD, MPH

Professor,

Director, UAB Minority Health International Research Training Program

Recipient, 2014 Ellen Gregg Ingalls/UAB National Alumni Society Award for Lifetime Achievement in Teaching

2018 Fulbright Specialist Scholar, Institute of Public Health, Ho Chi Minh City, Vietnam

Attachment

Submitted filename: Response to Reviewers.pdf

Decision Letter 1

Jenny Wilkinson

1 Dec 2020

PONE-D-20-21696R1

The Use of Complementary and Alternative Medicine among Hypertensive and Type 2 Diabetic Patients in Western Jamaica: A Mixed Methods Study

PLOS ONE

Dear Dr. Jolly,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 15 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Jenny Wilkinson, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Thank you for your revisions. These have now been reviewed by the original reviewers and some further comments provided. I now invite you to provide a further response to these comments.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: the sentence beginning line 66 can be rewritten so it is not run-on: "A survey conducted in 2000 examining use of herbal remedies from both urban and rural Jamaicans found that 100% of participants used herbs".

"advice" should be "advise" line 266.

"Warfarin" should be "warfarin" line 349.

i think the statements made in lines 367-368 and 395-397 are incorrect, participants did report experiences with and/or seem to suspect the prospect of synergistic effects of medications and herbs leading to hypotension and hypoglycemia.

Reviewer #2: Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics

i. The manuscript will sound after addressing the comments.

• Sample size of 60 questionnaires and 25 FGD not enough, maybe Author should explain how is attained to that sample size (state the formula employed),

• Sampling techniques and procedures didn't clearly explain

• Some information presented in the results section while do not find in the table and the author declared that they are not there, so I don’t know why presented in the section while are not there.

ii. This work needs more information than what has been presented in the analyzed data, possibly the tool used missed some questions to grasp those information. For instance the author presented some information in the result text while are not found in the table and she/he declared that data not found.

iii. State when and for how long did you collect the data

iv. The manuscript needs an English native speaker to make it reader friendly and understandable.

v. The manuscript lacks novel part.

vi. Find other comments on the manuscript.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Feb 8;16(2):e0245163. doi: 10.1371/journal.pone.0245163.r004

Author response to Decision Letter 1


22 Dec 2020

December 21, 2020

RE: PONE-D-20-21696

The Use of Complementary and Alternative Medicine among Hypertensive and Type 2 Diabetic Patients in Western Jamaica: A Mixed Methods Study

Jenny Wilkinson, PhD

Academic Editor, PLOS ONE

Dear Dr. Wilkinson,

Thank you for sending the second set of comments from the reviewers of our paper submitted to PLOS ONE. We have made the corrections requested by the academic editor and the reviewer(s) and have attached a highlighted copy of the manuscript that highlights changes made to the original version labeled as 'Revised Manuscript with Track Changes' and an unmarked version of the revised paper labeled 'Manuscript'. This is a point-by-point Response to Reviewers detailing the revisions that have been made and highlighted in the manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

________________________________________

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

________________________________________

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

________________________________________

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

________________________________________

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

________________________________________

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: the sentence beginning line 66 can be rewritten so it is not run-on: "A survey conducted in 2000 examining use of herbal remedies from both urban and rural Jamaicans found that 100% of participants used herbs".

Response: We thank the reviewer and have revised the sentence to read “A survey that examined the use of herbal remedies among rural and urban Jamaicans of varying socioeconomic groups found that 100% of the participants used herbs [8].”

"advice" should be "advise" line 266.

Response: We thank the reviewer and have made this correction.

"Warfarin" should be "warfarin" line 349.

Response: We have made this correction.

i think the statements made in lines 367-368 and 395-397 are incorrect, participants did report experiences with and/or seem to suspect the prospect of synergistic effects of medications and herbs leading to hypotension and hypoglycemia.

Response: We thank the reviewer for this observation and have deleted these statements.

Reviewer #2: Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics

i. The manuscript will sound after addressing the comments.

• Sample size of 60 questionnaires and 25 FGD not enough, maybe Author should explain how is attained to that sample size (state the formula employed),

• Sampling techniques and procedures didn't clearly explain

Response: We have revised the explanation in the methods section (page 5) and added references to justify the sample sizes as follows: “An exploratory design was used for the quantitative portion of this study (Creswell, J. W. and V. L. Plano Clark (2018). Prior studies suggest the sample size (N=60) is sufficient since the exploratory nature of the quantitative survey is the first stage of data collection and provides a rationale for defining future hypotheses for other stages of study (Kutner et al. 1999). In the concurrent quantitative-qualitative design, a smaller qualitative data design sample (N=25) was determined as sufficient (Creswell, J. W. and V. L. Plano Clark (2018).

References:

• Kutner JS, Steiner JF, Corbett KK, Jahnigen DW, Barton PL. Information needs in terminal illness. Soc Sci Med. 1999;48(10):1341-1352.

• Creswell JW, Clark VLP. Designing and conducting mixed methods research. 3rd edition. SAGE Publications, Inc. 2018

• Some information presented in the results section while do not find in the table and the author declared that they are not there, so I don’t know why presented in the section while are not there.

ii. This work needs more information than what has been presented in the analyzed data, possibly the tool used missed some questions to grasp those information. For instance the author presented some information in the result text while are not found in the table and she/he declared that data not found.

Response: We have added a table (Table 3) to the paper that shows the total number of participants who selected each herb and total numbers stratified by disease group. These data are for reporting only and not for analysis, so no data analysis was conducted and no data were missed (pages 11-12).

iii. State when and for how long did you collect the data

Response: We have added the dates of the study as May to August 2018 to both the abstract and methods (page 4).

iv. The manuscript needs an English native speaker to make it reader friendly and understandable.

Response: We are native English speakers and professionals. We have re-read and revised the paper to make it more understandable.

v. The manuscript lacks novel part.

Response: This is the first mixed-methods study on CAM use by HTN and T2DM patients in western Jamaica and provides the basis for future studies and interventions on alternative treatments. We agree with the reviewer that we did not expressly highlight the novelty of this study. We have revised the conclusion of the abstract to read “This study is novel in that it provides useful insights into perceptions and use of alternative treatments by patients that can be used by HCPs in developing appropriate interventions to encourage proper use of prescription medicines and CAM resulting in improved management of these chronic diseases” (pages 2-3).

We have also revised the Conclusion section of the paper to highlight that “the findings from this study indicate the need to include salient information on CAM in the professional curricula of HCPs and can be used to develop appropriate interventions to ensure the proper use of prescription medicines and CAM. This should result in improved management of T2DM and HTN among patients” (page 23).

vi. Find other comments on the manuscript.

Response:

________________________________________

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

Thank you for your kind consideration.

Respectfully,

Pauline Jolly, PhD, MPH

Professor,

Director, UAB Minority Health International Research Training Program

Recipient, 2014 Ellen Gregg Ingalls/UAB National Alumni Society Award for Lifetime Achievement in Teaching

2018 Fulbright Specialist Scholar, Institute of Public Health, Ho Chi Minh City, Vietnam

Attachment

Submitted filename: Response to Reviewers.pdf

Decision Letter 2

Jenny Wilkinson

23 Dec 2020

The Use of Complementary and Alternative Medicine among Hypertensive and Type 2 Diabetic Patients in Western Jamaica: A Mixed Methods Study

PONE-D-20-21696R2

Dear Dr. Jolly,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Jenny Wilkinson, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for responding to reviewer comments and revising your manuscript, these have satisfactorily addressed the issues raised.

Reviewers' comments:

Acceptance letter

Jenny Wilkinson

6 Jan 2021

PONE-D-20-21696R2

The Use of Complementary and Alternative Medicine among Hypertensive and Type 2 Diabetic Patients in Western Jamaica: A Mixed Methods Study

Dear Dr. Jolly:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Jenny Wilkinson

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Dataset. CAM dataset HTN & T2DM Jamaica.

    (XLSX)

    S1 File. Survey used in study.

    (PDF)

    S2 File. Focus group discussion guide.

    (DOCX)

    Attachment

    Submitted filename: PONE-D-20-21696_reviewer.pdf

    Attachment

    Submitted filename: Response to Reviewers.pdf

    Attachment

    Submitted filename: Response to Reviewers.pdf

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES